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ABSTRACT 
 
Cyclooxygenase-2 is involved in the inflammatory component of the ischemic cascade, playing an 
important role in the delayed progression of the brain damage. The present study evaluated the 
pharmacological effects of the selective cyclooxygenase-2 inhibitor nimesulide on delayed neuronal 
death of hippocampal CA1 neurons following transient global cerebral ischemia in gerbils. 
Administration of therapeutically relevant doses of nimesulide (3, 6 and 12 mg/kg; i.p.) 30 minutes 
before ischemia and at 6, 12, 24, 48 and 72 h after ischemia significantly (P<0.01) reduced hippocampal 
neuronal damage. Treatment with a single dose of nimesulide given 30 min before ischemia also 
resulted in a significant increase in the number of healthy neurons in the hippocampal CA1 sector 7 days 
after ischemia. Of interest is the finding that nimesulide rescued CA1 pyramidal neurons from ischemic 
death even when treatment was delayed until 24 h after ischemia (34 ± 9 % protection). Neuroprotective 
effect of nimesulide is still evident 30 days after the ischemic episode, providing the first experimental 
evidence that cyclooxygenase-2 inhibitors confer a long lasting neuroprotection. Oral administration of 
nimesulide was also able to significantly reduce brain damage, suggesting that protective effects are 
independent of the route of administration. The present study confirms the ability of cyclooxygenase-2 
inhibitors to reduce brain damage induced by cerebral ischemia and indicates that nimesulide can 
provide protection when administered for up to 24 h post-ischemia. 
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1. INTRODUCTION 
 
Transient global cerebral ischemia is produced when the brain is deprived temporarily of oxygen and 
glucose. In humans after cardiac arrest with resuscitation or cardiopulmonary bypass surgery, cerebral 
ischemia can lead to problems with cognition and memory, to serious neurological problems such as 
sensorimotor deficits and seizures, and to death (Levy et al., 1985; Petito et al., 1987).  
In humans and in animals subjected to transient forebrain ischemia, specific neurons degenerate 
following the ischemic episode (Kirino, 1982, 2000; Pulsinelli et al., 1982; Petito et al., 1987). The 
cornu Ammonis 1 (CA1) neurons of the hippocampus are widely regarded as among the most vulnerable 
in the mammalian brain to ischemia (Pulsinelli et al., 1982; Kirino, 1982). Delayed hippocampal damage 
is observed 3 to 7 days after the insult in CA1 pyramidal neurons (Kirino, 1982), suggesting that 
mechanisms that develop slowly after ischemia have an important role in ischemic neuronal demise.  
Several lines of recent evidences have shown that several pro-inflammatory genes or mediators, such as 
inducible nitric oxide synthase (iNOS), cyclooxygenase-2 and cytokines (e.g., tumor necrosis factor α 
and interleukin-1β) are strongly expressed in the ischemic brain (Ohtsuki et al., 1996; Koistinaho and 
Hökfelt, 1997; Barone and Feuerstein, 1999). Inflammation is now recognized as a significant 
contributing mechanism in cerebral ischemia because anti-inflammatory compounds or inhibitors of 
iNOS and cyclooxygenase-2 have been proven to reduce ischemic brain damage (Nogawa et al., 1997; 
Iadecola, 1997; Nakayama et al., 1998).  
Nimesulide (N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide) is a non-steroidal anti-inflammatory 
drug with potent effects, showing a high affinity and selectivity for cyclooxygenase-2 (Rabasseda, 1996; 
Cullen et al., 1998), but other mechanisms have been proposed to explain its mode of action: 1) 
inhibition of tumor necrosis factor α production (Azab et al., 1998), 2) antioxidant properties (Facino et 
al., 1993), 3) inhibition of the production of platelet activating factor (Tool and Verhoeven, 1995) and 4) 
reduction of the release of superoxide anions and other toxic substances from neutrophils (Bevilacqua et 
al., 1994). Nimesulide readily crosses the intact blood-brain barrier in both humans and rodents 
(Taniguchi et al., 1997; Cullen et al., 1998) .  
Recently, several studies have demonstrated a marked neuroprotective effect of nimesulide on chronic 
cerebral hypoperfusion (Wakita et al., 1999), kainate-induced excitotoxicity (Candelario-Jalil et al., 
2000) and quisqualic acid-induced neurodegeneration in rats (Scali et al., 2000). 
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In the light of these evidences, the present study was undertaken to investigate the effects of clinically 
relevant doses of nimesulide on the delayed neuronal death of CA1 pyramidal cells in the gerbil 
hippocampus following global ischemia. To our knowledge, there is no previous study on the effects of 
nimesulide against neuronal damage after focal or global cerebral ischemia. 
 
2. MATERIALS AND METHODS 
2.1. Animals and surgical procedures 
Studies were performed in accordance with the Declaration of Helsinki and with the Guide for the Care 
and Use of Laboratory Animals as adopted and promulgated by National Institutes of Health (Bethesda, 
MD, USA). Our institutional animal care and use committee approved the experimental protocol (No. 
01/98). A total of 111 male Mongolian gerbils (Meriones unguiculatus) weighing 60-75 g at the time of 
surgery were used in this study. These animals were housed four per cage, exposed to a 12-h light: 12-h 
dark cycle, and had free access to food and water throughout the study period. The gerbils were 
anesthetized with chloral hydrate (300 mg/kg, i.p.) and subjected to transient forebrain ischemia exactly 
as in our previous reports (Candelario-Jalil et al., 2001, 2002; Martínez et al., 2001). Briefly, in the 
supine position, a midline ventral incision was made in the neck. Both common carotid arteries were 
exposed, separated carefully from the vagus nerve, and occluded for 5 minutes with microaneurysmal 
clips (Sugita, Japan), which consistently resulted in delayed neuronal death in the CA1 region of the 
hippocampus (Kirino, 1982; Candelario-Jalil et al., 2002). Blood flow during the occlusion and 
reperfusion after removal of the clips was visually confirmed and the incision was closed with 4-0 silk 
sutures. In sham-operated animals, the arteries were freed from connective tissue but were not occluded.  
The onset of cerebral ischemia was associated with a brief period of panting breathing and body 
movements followed by quiescence. Successful occlusion of both common carotid arteries was evident 
with the rapid onset of complete bilateral ptosis and the adoption of a ‘hunched’ posture. Only animals 
showing this behavior were considered in this study (Martí et al., 2001; Martínez et al., 2001).  
The rectal temperature was carefully monitored and maintained at 37 ± 0.5°C using an incandescent 
lamp and the animals were allowed to recover on an electrical heated blanket. In addition, rectal 
temperature was monitored at 6-h intervals for 3 days of reperfusion in all experimental groups.  
 
2.2. Experimental protocols  
2.2.1. Experiment 1: Dose-response study of nimesulide treatment 
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This experiment was undertaken to investigate the effects of different doses of nimesulide on neuronal 
damage after ischemia. Since nimesulide is usually administered to patients at a dosage between 3 and 6 
mg/kg for the treatment of inflammatory conditions (Rabasseda, 1996; Cullen et al., 1998), the 
following experimental groups were prepared: a sham-operated group (n=5), an ischemic group treated 
with the vehicle of nimesulide (polyvinylpyrrolidone, n=7) and three groups of ischemic gerbils treated 
with nimesulide at doses of 3 (n=6), 6 (n=8) and 12 mg/kg (n=7) given intraperitoneally. Nimesulide or 
vehicle was administered 30 minutes before ischemia and again at 6, 12, 24, 48 and 72 h of reperfusion. 
This treatment schedule was based on our previous experience with another cyclooxygenase-2 inhibitor 
(Candelario-Jalil et al., 2002). In addition, we reasoned that if cyclooxygenase-2 is one of a select few 
proteins that still remains upregulated in CA1 neurons even at 3 days after global ischemia (Nakayama 
et al., 1998; Koistinaho et al., 1999), the nimesulide treatment should be maintained for several days 
after the ischemic episode. We also performed an experiment in which nimesulide was given as a single 
dose.  
 
2.2.2. Experiment 2: Effects of a single dose of nimesulide 
The effect of a single dose of nimesulide (6 mg/kg; i.p.) given 30 minutes before the onset of ischemia 
was examined (n=7). The dose of nimesulide used in this experiment was based on results obtained from 
Experiment 1 (see Fig. 1). A single injection vehicle-treated group was also included (n=7).  
 
2.2.3. Experiment 3: Time window for nimesulide treatment in gerbils subjected to transient forebrain 
ischemia 
In this experiment, the effect of nimesulide was studied in a situation in which its first administration 
was delayed for 6 to 24 h after ischemia. Nimesulide (6 mg/kg; i.p.) was dosed 6 (n=9), 12 (n=9) and 24 
h (n=7) after the induction of ischemia, followed by additional doses at 24, 48 and 72 h of reperfusion. 
 
2.2.4. Experiment 4: Analysis of duration of the neuroprotective action of nimesulide 
This experiment was undertaken to examine whether the protective effect of nimesulide was transitory 
or long lasting. Nimesulide (6 mg/kg; i.p.) was administered as in Experiment 1, but gerbils were 
sacrificed 30 days after the onset of blood flow (n=7). A vehicle-treated ischemic control group was also 
included (n=7). 
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2.2.5. Experiment 5: Oral administration of nimesulide 
Since nimesulide is commonly administered to patients in oral dosage forms, in this experiment we 
investigated whether the protective effects of nimesulide are dependent of the route of administration. 
This experiment followed the exact same procedure as Experiment 1, except that nimesulide was dosed 
orally (6 mg/kg, n=6). In the ischemic control group (n=7) the animals were treated orally with vehicle 
(0.5% carboxymethylcellulose solution) for 3 days. 
 
2.3. Histologic analysis 
Gerbils were sacrificed 7 or 30 days (in Experiment 4) after ischemia. Animals were anesthetized with 
urethane (0.8 g/kg; i.p.) and perfused transcardially with cold saline followed by 4% formalin in 
phosphate-buffered saline (0.1 M; pH 7.4). The brains were removed from the skull and fixed in the 
same fixative for 24 h. Thereafter, the brains were embedded in paraffin and representative coronal 
sections (5-μm thick), which included the dorsal hippocampus (1.0-2.2 mm posterior to bregma), were 
obtained with a rotary microtome (Leica, Model RM2135, Meyer Instruments, Houston, TX, USA). 
Tissue sections were stained with hematoxylin and eosin. The hippocampal damage was determined by 
counting the number of intact neurons in the stratum pyramidale within the CA1 subfield at a 
magnification of 40x (Lee et al., 2000). Only neurons with normal visible nuclei were counted. The 
mean number of CA1 neurons per mm linear length for both hemispheres in three adjacent sections of 
dorsal hippocampus was calculated for each group of animals. An observer who was unaware of the 
drug treatment for each gerbil made all assessments of histological sections. 
 
2.4. Effect of nimesulide on physiologic variables 
The possible effect of nimesulide on several physiologic variables was studied in additional animals. 
Mean arterial blood pressure, blood glucose, hematocrit, blood pH and blood gases (pO2 and pCO2) 
were measured at baseline, during the occlusion and 30 min after each vehicle or nimesulide (12 mg/kg; 
i.p.) administration following the exact treatment paradigm of the Experiment 1.  
 
2.5. Statistical analysis 
The data of this study was expressed as a mean value ± S.D. Statistical analysis was performed using 
one-way analysis of variance (ANOVA) followed by Student-Newman-Keuls post-hoc test and 
significance refers to results where P<0.05 was obtained. 
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2.6. Chemical supplies 
Nimesulide was kindly provided by Gautier-Bagó Laboratories (Buenos Aires, Argentina). 
Polyvinylpyrrolidone and carboxymethylcellulose were obtained from BDH Chemicals (Poole, 
England). All other reagents were purchased from Sigma Chemical Co. (Saint Louis, MO, USA). 
 
3. RESULTS 
3.1. Effects of different doses of nimesulide on CA1 hippocampal injury (Experiment 1) 
Seven days after the ischemic episode, widespread damage to the CA1 region of the hippocampus was 
evident in the brains of the vehicle-treated group. Pyramidal neurons either presented a densely stained 
shrunken appearance with minimal cytoplasm or, in many instances, had disappeared. Some of these 
animals displayed a nearly total necrosis or loss of the CA1 pyramidal cells.  
Delayed neuronal death in CA1 hippocampal sector was significantly reduced (P<0.01) by 
administration of nimesulide at the three doses examined (3, 6 and 12 mg/kg; i.p.; 47 ± 3 %, 49 ± 10 % 
and 52 ± 9 % of protection, respectively) as shown in Fig. 1. No statistically significant difference was 
detected in the neuronal density between the three doses of nimesulide (Fig. 1).  
Taking into account that previous studies have found marked neuroprotective effects with nimesulide at 
the dose of 6 mg/kg in different models of brain injury (Candelario-Jalil et al., 2000; Cernak et al., 
2001), we decided to select the dose of 6 mg/kg to further evaluate the effects of nimesulide using other 
treatment paradigms. 
 
3.2. Effects of a single dose of nimesulide  
Administration of a single dose of nimesulide (6 mg/kg; i.p.) 30 minutes before ischemia resulted in a 
significant (P<0.05) reduction in the extent of CA1 neuronal loss as compared to the vehicle-treated 
group (Fig. 1), but this effect was much more evident when the treatment is continued for 3 days after 
the onset of reperfusion (Fig. 1), indicating that the protection depends on treatment duration. 
 
3.3. Time window for nimesulide neuroprotection in gerbils subjected to 5 min transient cerebral 
ischemia (Experiment 3) 
In this experiment, we tried to determine whether nimesulide could protect neurons when applied 
several hours after ischemia. To answer this question nimesulide (6 mg/kg; i.p.) was administered 6, 12 
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and 24 h after ischemia. All treatment schedules led to statistically significant increase (P<0.05) in the 
number of healthy neurons in the CA1 subfield (Fig. 2). When nimesulide administration is delayed 
until 6-12 h after the insult, the neuroprotection is similar (49 ± 6 and 50 ± 14 %, respectively) to that 
seen in the group in which the treatment started 30 minutes before ischemia (48 ± 11%), although an 
overall decline of efficacy with post-treatment time was observed (Fig. 2).  
 
3.4. Duration of the neuroprotective effect of nimesulide (Experiment 4) 
At 30 days after 5 min ischemia, brains of gerbils given vehicle or nimesulide (6 mg/kg; i.p.; for 3 days 
post-ischemia) were studied to determine the number of surviving neurons in the CA1 hippocampal 
subfield. Cell counting revealed that the neuroprotective effect of nimesulide remained virtually 
unchanged over the 30 days time period after the ischemic insult (Fig. 3). These data suggest that the 
protective effects of nimesulide are sustained over time.  
 
3.5. Oral administration of nimesulide 
Oral treatment with nimesulide (6 mg/kg; 30 min pretreatment) significantly attenuated (P<0.05) 
neuronal damage in the CA1 region of the hippocampus as evaluated by histology (vehicle 64 ± 8 
neurons/mm vs nimesulide 138 ± 11 neurons/mm). The neuroprotection was similar to that obtained 
with intraperitoneal administration (133 ± 10 neurons/mm), indicating that the protective effect is 
independent of the route of administration. 
 
3.6. Physiologic variables in ischemic animals after nimesulide treatment 
There were no significant differences in arterial blood pressure, blood glucose, hematocrit, blood pH or 
blood gases between vehicle and nimesulide groups (Table 1). 
 
4. DISCUSSION 
 
The core finding of the present study is that administration of clinically relevant doses of nimesulide is 
remarkably neuroprotective in gerbils against transient cerebral ischemia. There is no previous report on 
the protective effects of this cyclooxygenase-2 inhibitor in brain ischemia. Nimesulide rescued CA1 
pyramidal neurons from ischemic death even when treatment was delayed until 24 h after ischemia. Of 
special interest is the finding that the protection is still observed 30 days after restoration of blood flow, 
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providing the first experimental evidence that cyclooxygenase-2 inhibitors confer a long lasting and 
likely permanent neuroprotection and do not merely delay cell death.  
 
Although the neuroprotective effects of glutamate antagonists in animal models of cerebral ischemia 
have been remarkable (Muir and Lees, 1995), their clinical benefits are limited because the 
neuroprotection is not long lasting (Colbourne et al., 1999) and most of them show severe side effects.  
 
Nimesulide has been widely used in several European countries for 20 years to treat inflammatory 
conditions and fever (Cullen et al., 1998). It is important to note that the neuroprotective effects of 
nimesulide against ischemic damage (Fig. 1) were observed at doses that are well tolerated in patients 
with minimal side effects.  
 
Hypothermia during ischemia prevents ischemic injury (reviewed by Corbett and Thornhill, 2000). 
Unless the brain temperature is carefully controlled, neuroprotection could easily result from drug-
induced hypothermia rather than a specific pharmacological effect. The protection conferred by 
nimesulide is not attributable to effects on body temperature because this variable was carefully 
monitored and did not differ between treated and non-treated groups (data not shown).  
 
The protective time window of nimesulide treatment, until 24 h after the onset of reperfusion, is 
clinically exploitable in the context of cardiac arrest with resuscitation. Whereas resuscitative efforts 
often restore perfusion to the brain, still a considerable number of patients end up having permanent 
cerebral damage because only minutes of global ischemia can lead to permanent brain injury (Petito et 
al., 1987). Thus, if nimesulide proves as protective in humans as in rodents, resuscitation followed by 
nimesulide treatment would save a number of patients from permanent cerebral damage.  
 
The inflammatory mediator pathway has been implicated as a potential contributor to the progression of 
ischemic injury (del Zoppo et al., 2000; Iadecola and Alexander, 2001). Cyclooxygenase-2 mRNA and 
protein levels have been shown to be significantly increased within neurons and vascular cells after 
cerebral ischemia and other insults that result in neurodegeneration (Planas et al., 1995; Nogawa et al., 
1997; Sanz et al., 1997; Nakayama et al., 1998; Koistinaho et al., 1999; Iadecola et al., 1999; Dore et al., 
2001). Cyclooxygenase-2 has become the focus of attention because it is the rate-limiting enzyme 
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involved in arachidonic acid metabolism, thereby generating prostaglandins and thromboxanes, 
molecules that play important roles in supporting and sustaining the inflammatory response (Vane et al., 
1998).  
 
Our present result that nimesulide protects CA1 neurons when administered several hours after ischemia 
(Fig. 2) is consistent with previous studies which have found that cyclooxygenase-2 selective inhibitors 
have a wide therapeutic window for protection in both focal (Nogawa et al., 1997) and global cerebral 
ischemia (Candelario-Jalil et al., 2002). A similar long therapeutic time window in brain ischemia has 
been reported for other pharmacological strategies aimed at reducing post-ischemic inflammation 
(Iadecola et al., 1995; Nagayama et al., 1998; Cash et al., 2001). In addition, several studies have found 
neuroprotective effects of different compounds when administered after ischemia (Jiang et al., 1998; 
Yrjanheikki et al., 1999; Haag et al., 2000; Phillips et al., 2000; Zhang et al., 2001; Snider et al., 2001; 
Lavie et al., 2001; Mary et al., 2001), suggesting that brain injury produced by cerebral ischemia 
develops over a period of hours to days after the primary event.  
 
Repeated treatments with nimesulide for the first three days after ischemia afforded a more remarkable 
neuroprotection than the administration of a single dose given before the insult (Fig. 1). These data show 
the importance of continuous long-term administration after ischemic damage in clinical trials to achieve 
the maximal beneficial effects of neuroprotection by nimesulide to target the delayed progression of 
damage. 
 
Increased cyclooxygenase-2 activity and enhanced release of prostanoids have been shown to be 
associated with the generation of highly reactive oxygen species, which have potent deleterious effects 
on cells. Recently, we have found that administration of the cyclooxygenase-2 inhibitor nimesulide at a 
dose proven to confer protection in the present study (6 mg/kg), is able to reduce hippocampal oxidative 
damage following excitotoxic brain injury (Candelario-Jalil et al., 2000), which is a key pathological 
event of cerebral ischemia. This latter observation is particularly relevant in view of evidence showing 
that oxidative stress is implicated in the development and progression of apoptotic cell death in the 
central nervous system (Sastry and Rao, 2000) and that activation of cyclooxygenase-2 is required for 
execution of oxidative neuronal death (Lee et al., 2001). Further experiments are needed to clarify the 
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effects of selective inhibition of cyclooxygenase-2 on markers of oxidative stress in the ischemic brain 
and its relation to neuronal death after ischemia. 
 
Several additional mechanisms could account for the neuroprotection conferred by nimesulide in global 
cerebral ischemia. The possibility that nimesulide diminished neuronal loss through reduction of 
oxidative damage, inhibition of pro-inflammatory cytokines production and blockade of apoptotic 
pathways cannot be excluded.  
 
In summary, the present study has demonstrated a marked neuroprotective effect of nimesulide on the 
gerbil CA1 hippocampal neurons after transient forebrain ischemia at therapeutically relevant doses 
when administered even 24 h after the initial ischemic episode. Of great importance is the finding that 
neuroprotection conferred by nimesulide is long lasting and also observed with oral treatment. Our 
results suggest that cyclooxygenase-2 selective inhibition by nimesulide may be of therapeutic benefit in 
the treatment of global cerebral ischemia.  
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Table 1. Physiologic variables in additional gerbils (n=6 per group) given nimesulide (12 mg/kg; i.p.) 
30 min before carotid occlusion and at 6, 12, 24, 48 and 72 h of reperfusion.  
Time (h) Treatment Blood 
pressure 
(mmHg) 
Blood 
glucose 
(mmol/L) 
Hematocrit 
(%) 
pH pO2 
(mmHg) 
pCO2 
(mmHg) 
Vehicle 69 ± 5 5.0 ± 0.6 47.9 ± 0.9 7.33 ± 0.03 128 ± 24 34.8 ± 6.5 Baseline 
Nimesulide 67 ± 6 5.3 ± 0.8 49.3 ± 0.5 7.35 ± 0.04 132 ± 19 32.5 ± 5.8 
Vehicle 86 ± 8 4.9 ± 1.4 48.0 ± 0.7 7.31 ± 0.05 107 ± 41 26.8 ± 7.8 During 
Occlusion 
Nimesulide 82 ± 11 5.2 ± 0.7 49.1 ± 0.9 7.24 ± 0.02 114 ± 15 28.4 ± 6.9 
Vehicle 57 ± 15 4.8 ± 0.6 47.2 ± 0.6 7.29 ± 0.06 156 ± 22 23.4 ± 8.9 30 min after 
reperfusion 
Nimesulide 59 ± 19 5.1 ± 1.1 49.2 ± 0.4 7.26 ± 0.07 153 ± 16 25.2 ± 3.7 
Vehicle 62 ± 12 5.6 ± 0.7 48.3 ± 0.5    6 h 30 min 
Nimesulide 69 ± 9 5.0 ± 0.8 47.5 ± 0.7    
Vehicle 70 ± 14 4.1 ± 0.9 48.7 ± 0.4    12 h 30 min 
Nimesulide 62 ± 9 5.2 ± 1.0 49.1 ± 0.8    
Vehicle 58 ± 13 4.0 ± 1.5 48.2 ± 0.5    24 h 30 min 
Nimesulide 64 ± 9 4.7 ± 0.8 48.5 ± 0.6    
Vehicle 69 ± 8 4.8 ± 0.4 48.6 ± 0.5    48 h 30 min 
Nimesulide 70 ± 13 5.3 ± 0.7 47.3 ± 0.4    
Vehicle 66 ± 12 4.8 ± 1.2 48.8 ± 0.2    72 h 30 min 
Nimesulide 67 ± 5 5.2 ± 1.4 49.2 ± 0.5    
Values are mean ± S.D. Monitoring of physiological variables was performed at 30 min after nimesulide 
or vehicle injection. No statistically significant differences were found between gerbils treated with 
vehicle or nimesulide (n=6 per group) (P>0.05, Student’s t test).  
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Fig. 1. Effect of clinically relevant doses (3, 6 and 12 mg/kg; i.p.) of the selective cyclooxygenase-
2 inhibitor nimesulide on the number of surviving neurons in the CA1 hippocampal subfield 7 days 
after 5 min transient global cerebral ischemia in Mongolian gerbils. Repeated treatment with 
nimesulide for 3 days after ischemia (30 min before ischemia and after 6, 12, 24, 48 and 72 h of 
reperfusion) afforded a more remarkable neuroprotective effect than the administration of a single 
dose (6 mg/kg; i.p.) given 30 min before ischemia. Values are mean counts of normal-appearing 
CA1 neurons per mm linear length ± S.D. *P<0.05 and **P<0.01 for the comparison between 
nimesulide-treated and vehicle-treated groups. &P<0.05 with respect to single injection vehicle-
treated group. (One-way ANOVA followed by Student-Newman-Keuls post-hoc test).  
 
 
 
 
Sham   Vehicle 3             6            12 
Nimesulide (mg/kg; i.p.) 
Repeated doses for 3 
days after ischemia 
Nimesulide 
6 mg/kg; i.p. 
Single dose 
Before 
ischemia
** 
**
**
& 
 Vehicle 
Single 
dose 
C
A
1 
ne
ur
on
s/
m
m
 
Candelario-Jalil et al., 2002                                                      Eur. J. Pharmacol. 453(2-3):189-95 (2002) 
 
 
17
 
0
50
100
150
200
250
300
 
 
 
Fig. 2. Time-dependency of the neuroprotective effect of nimesulide on 5 min of transient global 
ischemia. The drug (6 mg/kg; i.p.) was administered 6 (n=9), 12 (n=9) and 24 hours (n=7) after 
restoration of blood flow. When nimesulide treatment is delayed until 12 h after ischemia, 
neuroprotection is similar to gerbils pretreated with the drug. Data are always expressed as 
healthy neurons per mm linear length of the hippocampal CA1 region ± S.D. *P<0.05 and 
**P<0.01 with respect to vehicle-treated group (ANOVA followed by Student-Newman-Keuls 
multiple comparison test).  
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Fig. 3. Effect of nimesulide (6 mg/kg; i.p., for 3 days post-ischemia) on the number of 
surviving neurons in the CA1 hippocampal region 30 days after the ischemic episode. 
Cell counting revealed that the neuroprotective effect of nimesulide remained 
virtually unchanged over the 30 days time period after ischemia. Values are mean 
counts of healthy CA1 neurons per mm linear length ± S.D. **P<0.01 with respect to 
vehicle-treated animals. One-way ANOVA followed by Student-Newman-Keuls 
multiple comparison test.    
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